Markers of fibrosis, renal function in ischemic chronic heart failure in late stage of the postinfarction remodeling
DOI:
https://doi.org/10.14739/2310-1210.2015.4.50309Keywords:
Heart Failure, Biomarkers, Fibrosis, KidneyAbstract
Aim. Investigate the levels of fibrosis markers, state of renal function in patients with chronic heart failure in late stage of the postinfarction remodeling.
Methods and results. Features of the fibrosis markers and renal function depending on the prior myocardial infarction were identified in 318 patients with ischemic chronic heart failure using ELISA, echocardiography. Activity biomarkers (galectin-3, ST2, NGAL, PICP, cystatin C), estimated glomerular filtration rate, structural and functional parameters of the heart were studied. It was established that the presence of prior myocardial infarction in chronic heart failure was accompanied by the increasing of NT-proBNP, galectin-3, PICP, NGAL and was characterized by structural remodeling of the left atrium with increased systolic pressure in the pulmonary artery, the deterioration of systolic and diastolic function.
Conclusion. Galectin-3, PICP, NGAL can be used as new therapeutic targets in patients with myocardial infarction to reduce the degree of fibrosis, inflammation and for preventing development of chronic heart failure and renal dysfunction.
References
Mozaffarian, D., Benjamin, E., Go, A., Arnett, D., Blaha, M., Cushman, M., et al. (2015). Executive Summary: Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association. Circulation, 131(4), 434–441. doi:10.1161/cir.0000000000000157.
Gajarsa, J., & Kloner, R. (2010). Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Failure Reviews, 16(1), 13–21. doi:10.1007/s10741-010-9181-7
Fraccarollo, D., Galuppo, P., & Bauersachs, J. (2012). Novel therapeutic approaches to post-infarction remodelling. Cardiovascular Research, 94(2), 293–303. doi:10.1093/cvr/cvs109.
Ferroni, P., Basili, S., Martini, F., Cardarello, C., Ceci, F., Di Franco, M., et al. (2003). Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. Journal Of Investigative Medicine, 51(05), 295. doi:10.2310/6650.2003.3563.
Metra, M., Cotter, G., Gheorghiade, M., Dei Cas, L., & Voors, A. (2012). The role of the kidney in heart failure. European Heart Journal, 33(17), 2135–2142. doi:10.1093/eurheartj/ehs205.
Voronkov, L. G., Amosova, K. M., Bahrii, A. E., Dziak, H. V., Diadyk, O. I., Zharinov, O. Y., et al. (2012). Rekomendatsii z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti [Guidelines for the diagnosis and treatment of chronic heart failure]. Sertseva nedostatnist, 3, 60–96 [in Ukrainian].
(2013). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3(1), 1–150. doi:10.1038/kisup.2012.73.
Gluba, A., Bielecka, A., Mikhailidis, D., Wong, N., Franklin, S., Rysz, J., & Banach, M. (2012). An update on biomarkers of heart failure in hypertensive patients. Journal Of Hypertension, 30(9), 1681–1689. doi:10.1097/hjh.0b013e3283569a9c.
Swartz, M., Fink, G., Sarwar, M., Hicks, G., Yu, Y., Hu, R., et al. (2012). Elevated Pre-Operative Serum Peptides for Collagen I and III Synthesis Result in Post-Surgical Atrial Fibrillation. Journal Of The American College Of Cardiology, 60(18), 1799–1806. doi:10.1016/j.jacc.2012.06.048.
Broch, K., Andreassen, A., Ueland, T., Michelsen, A., Stueflotten, W., Aukrust, P., et al. (2015). Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. International Journal Of Cardiology, 179, 378–384. doi:10.1016/j.ijcard.2014.11.003.
Richards, A., Di Somma, S., & Mueller, T. (2015). ST2 in Stable and Unstable Ischemic Heart Diseases. The American Journal Of Cardiology, 115(7), 48B–58B. doi:10.1016/j.amjcard.2015.01.041.
Lin, Y., Lin, L., Wu, Y., Chien, K., Lee, C., Hsu, R., et al. (2009). The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clinica Chimica Acta, 409(1–2), 96–99. doi:10.1016/j.cca.2009.09.001.
Lepojärvi, E., Piira, O., Pääkkö, E., Lammentausta, E., Risteli, J., Miettinen, J., et al. (2015). Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Frontiers In Physiology, 6. doi:10.3389/fphys.2015.00200.
Kirbiš, S., Gorenjak, M., & Sinkovič, A. (2015). The role of urine neutrophil gelatinase – associated lipocalin (NGAL) in acute heart failure in patients with ST – elevation myocardial infarction. BMC Cardiovasc Disord, 15(1). doi:10.1186/s12872-015-0054-9.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
